Fig 1.
Structure of the Markov model.
Table 1.
Baseline cohort characteristics.
Table 2.
Annual health state transition rates.
Table 3.
Annual health state utility values.
Table 4.
Annual health state costs.
Table 5.
Base-case analysis: Cost-effectiveness of DCV+ASV versus PR.
Table 6.
Base-case analysis: Lifetime risk of complications after treating with DCV+ASV and PR.
Fig 2.
Base-case analysis: Estimated incidence of HCV-related complications (compensated cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma) after treating with DCV+ASV.
Fig 3.
Base-case analysis: Estimated incidence of HCV-related complications (compensated cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma) after treating with PR.
Fig 4.
Univariate sensitivity analysis.
Fig 5.
Probabilistic sensitivity analysis: Cost-effectiveness scatter plots.